Leap Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 54

Employees

  • Stock Symbol
  • LPTX

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $2.11
  • (As of Monday Closing)

Leap Therapeutics General Information

Description

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Contact Information

Website
www.leaptx.com
Formerly Known As
HealthCare Pharmaceuticals, Dekkun Corp
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge, MA 02141
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Leap Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.11 $2.07 $1.24 - $5.00 $80.7M 38.3M 164K -$2.13

Leap Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (2,285) 25,595 (32,974) 161,704
Revenue 0 0 0 1,500
EBITDA (57,309) (85,426) (55,304) (40,550)
Net Income (53,371) (81,414) (54,596) (40,587)
Total Assets 57,963 72,825 70,353 117,911
Total Debt 584 262 678 469
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Leap Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Leap Therapeutics‘s full profile, request access.

Request a free trial

Leap Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Leap Therapeutics‘s full profile, request access.

Request a free trial

Leap Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-pr
Biotechnology
Cambridge, MA
54 As of 2023
00000
000000000 00000

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
000000000000000
Mountain View, CA
000 As of 0000
00000
00.000 0000-00-00
000000&0 00000

000000

eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ve
0000000000000
Andover, MA
00 As of 0000
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Leap Therapeutics Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Chemocentryx Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
Oncorus Formerly VC-backed Andover, MA 00 00000 000000000000 00000
Mustang Bio Corporation Worcester, MA 00 00000 000000000 00000
SAGE Therapeutics Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 41 competitors. Get the full list »

Leap Therapeutics Patents

Leap Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4398889-A1 Combination therapy Pending 10-Sep-2021 000000000
CA-3158661-A1 Methods of treating cancer using dkk-1-inhibitors Pending 22-Nov-2019 000000000
AU-2020386091-A1 Methods of treating cancer using dkk-1-inhibitors Pending 22-Nov-2019 000000000
EP-4061419-A1 Methods of treating cancer using dkk-1-inhibitors Pending 22-Nov-2019 000000000
US-20240141023-A1 Methods of treating cancer using dkk-1 inhibitors Pending 22-Nov-2019 C07K16/18
To view Leap Therapeutics’s complete patent history, request access »

Leap Therapeutics Executive Team (8)

Name Title Board Seat
Douglas Onsi JD Chief Executive Officer, President & Board Member
Augustine Lawlor Chief Operating Officer, Operations
Jason Baum Ph.D Chief Scientific Officer
Christine Granfield Executive & Vice President
Mark O'Mahony Chief Manufacturing Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Leap Therapeutics Board Members (9)

Name Representing Role Since
Christopher Mirabelli Ph.D Leap Therapeutics Chairman 000 0000
James Cavanaugh Ph.D HealthCare Ventures Board Member 000 0000
Joseph Loscalzo Ph.D Self Board Member 000 0000
Nissim Mashiach MacroCure Board Member 000 0000
Patricia Martin Leap Therapeutics Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Leap Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Leap Therapeutics Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Flame Biosciences 17-Jan-2023 0000000000 0000 Drug Discovery 0000000 0
MacroCure 23-Jan-2017 0000000000 Biotechnology 000000000
GITR 21-Jan-2016 000000 00 Drug Discovery 0000000 0
HealthCare Pharmaceuticals 21-Jan-2016 Merger of Equals Biotechnology
To view Leap Therapeutics’s complete acquisitions history, request access »

Leap Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Leap Therapeutics’s complete esg history, request access »

Leap Therapeutics FAQs

  • When was Leap Therapeutics founded?

    Leap Therapeutics was founded in 2011.

  • Who is the CEO of Leap Therapeutics?

    Douglas Onsi JD is the CEO of Leap Therapeutics.

  • Where is Leap Therapeutics headquartered?

    Leap Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Leap Therapeutics?

    Leap Therapeutics has 54 total employees.

  • What industry is Leap Therapeutics in?

    Leap Therapeutics’s primary industry is Biotechnology.

  • Is Leap Therapeutics a private or public company?

    Leap Therapeutics is a Public company.

  • What is Leap Therapeutics’s stock symbol?

    The ticker symbol for Leap Therapeutics is LPTX.

  • What is the current stock price of Leap Therapeutics?

    As of 22-Jul-2024 the stock price of Leap Therapeutics is $2.11.

  • What is the current market cap of Leap Therapeutics?

    The current market capitalization of Leap Therapeutics is $80.7M.

  • Who are Leap Therapeutics’s competitors?

    Chemocentryx, Oncorus, Mustang Bio, SAGE Therapeutics, and NexImmune are some of the 41 competitors of Leap Therapeutics.

  • What is Leap Therapeutics’s annual earnings per share (EPS)?

    Leap Therapeutics’s EPS for 12 months was -$2.13.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »